Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

GRI Bio, Inc.

NASDAQ: GRI · Life Sciences · 2 alerts · CIK 1824293

Share price
$1.40Close, Nov 16
Market cap
$3.06M
Shares outstanding
2.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All GRI Bio, Inc. filings on SEC EDGAR ↗

5:12 PM ET 10-Q
Financial Results

GRI Bio Q3 2026 Results: Net Loss of $1.51M, Loss Narrows

GRI Bio, Inc. reported a net loss of $5.15 million for the nine months ended September 30, 2026, a significant reduction from the $9.30 million loss in the prior year period, primarily due to lower research and development expenses. The company strengthened its liquidity through an ATM offering, ending the period with $9.47 million in cash and cash equivalents. GRI Bio remains a clinical-stage biopharmaceutical company with an accumulated deficit of $56.84 million and no significant revenue.

Key figure
Net loss $1.51M
5:13 PM ET 8-K
Shareholder Meeting

GRI Bio Shareholder Meeting

GRI Bio held its 2026 Annual Meeting of Stockholders where shareholders elected W. Marc Hertz and David Szekeres as Class III directors and ratified WithumSmith+Brown, PC as the independent auditor. Stockholders also approved an amendment to the 2018 Equity Incentive Plan, increasing the share reserve by 546,529 shares and extending the evergreen provision to 2036.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.